For decades, hormone therapy has been a common, yet often debated, treatment for managing menopause symptoms like hot flashes and bone loss. Recent shifts in medical understanding culminated in November with the FDA removing “black box” warnings about potential dementia risk linked to these therapies. Now,a thorough new analysis of over one million patients provides further reassurance,finding no important association between hormone therapy and increased risk of dementia or cognitive decline.
Menopause, a natural transition in a woman’s life, can sometimes be disruptive. It triggers hormonal changes that can lead to a variety of symptoms. Hormone therapy is often prescribed to alleviate these symptoms and reduce the risk of bone loss, but concerns have lingered regarding a potential link to dementia. Now, a new study offers reassurance, finding no evidence to support that connection.
Hormone Therapy: A Common Menopause Treatment With a History of Debate
“Menopause hormone therapy is widely used to manage the symptoms of menopause,” said Melissa Melville, lead author of the study. “However, its impact on memory, cognitive functions, and the risk of dementia remains one of the most debated topics in women’s health. Conflicting research and concerns about potential side effects have fueled public and medical discussion, leaving women and clinicians uncertain about whether hormone therapy could increase or reduce their risk of dementia.”
The debate surrounding hormone therapy has recently shifted, with the U.S. Food and Drug Administration (FDA) announcing in November the removal of boxed warnings from menopause hormone therapy products. According to a statement released with the study, these warnings related to “previously alleged potential long-term health risks, including an increased risk of dementia,” have now been refuted.
Menopause: No Link Found Between Hormone Therapy and Dementia Risk
To better understand the relationship between hormone therapy and dementia risk, researchers analyzed data from ten studies encompassing over one million patients. The analysis revealed “no significant association between menopause hormone therapy and the risk of dementia or mild cognitive impairment.” Further analyses, considering the timing, duration, and type of hormone treatment, also showed no significant effects. The study also found no evidence of a link between hormone therapy and dementia risk in women experiencing early menopause.
“This analysis will contribute to the development of future World Health Organization (WHO) recommendations on reducing the risk of cognitive decline and dementia, which are expected to be published in 2026,” the authors concluded. They emphasize, however, that additional “high-quality, long-term” research is needed to fully understand the long-term effects of menopause hormone therapy. The findings offer valuable insight for both healthcare providers and women considering hormone therapy as a treatment option, and could help shape future clinical guidelines.
